Boldine

Pharmacology & Research

Boldine is the principal aporphine alkaloid of boldo (Peumus boldus), and its defining property is being a potent chain-breaking radical-scavenging antioxidant ^{1Reference 1O’Brien P et al. · 2006Boldine and its antioxidant or health-promoting propertiesView study →}. Two clarifications frame the page. First, boldo’s severe reputation — hepatotoxicity and abortifacient risk — is largely a property of its essential oil, which is rich in the toxic terpene ascaridole, not of boldine; boldine is the water/alcohol-extractable leaf alkaloid and is comparatively low-toxicity. Second, the human evidence for boldo’s traditional digestive/choleretic use is for the herb/leaf, not the isolated alkaloid — all boldine-specific pharmacology below is preclinical. The one genuine isolate-level safety flag is a reproducible genotoxicity signal ^{16,17Reference 161994Evaluation of the genotoxic potential of boldine in mammalian cell systemsView study →Reference 171991Genotoxicity of the boldine aporphine alkaloid in prokaryotic and eukaryotic organismsView study →}.

1. Antioxidant / cytoprotective

Boldine’s most robust and reproducible property. It is a potent chain-breaking phenolic/aporphine scavenger ^{1Reference 1O’Brien P et al. · 2006Boldine and its antioxidant or health-promoting propertiesView study →} — protecting erythrocytes from free-radical lysis ^{2Reference 22000Protective effects of boldine against free-radical-induced erythrocyte lysisView study →}, inhibiting LDL oxidation ^{3Reference 32004Boldine inhibits LDL oxidationView study →}, and driving Nrf2/ARE cytoprotective signalling ^{5Reference 52026Boldine activates Nrf2/ARE to alleviate 5-fluorouracil-induced apoptosis and oxidative stressView study →}.

Gap: almost entirely in-vitro/ex-vivo, and boldine turns pro-oxidant at higher concentrations or in some redox contexts ^{4Reference 42008Antioxidant and pro-oxidant properties of boldine on hippocampal slicesView study →} — not a clean “more is better” antioxidant — with no human antioxidant-endpoint trial ^{1,4Reference 1O’Brien P et al. · 2006Boldine and its antioxidant or health-promoting propertiesView study →Reference 42008Antioxidant and pro-oxidant properties of boldine on hippocampal slicesView study →}.

2. Hepatoprotective / choleretic

The mechanistic basis for boldo’s traditional digestive use. Boldine increases bile flow via osmotic and FXR-dependent mechanisms ^{7Reference 72015Boldine enhances bile production via osmotic and FXR-dependent mechanismsView study →}, and protects against CCl₄ chronic liver injury via NF-κB ^{8Reference 82024Boldine protects against CCl₄-induced chronic liver injury via NF-κBView study →}, with the classic Peumus boldus extract showing hepatoprotection and anti-inflammation ^{6Reference 61991Hepatoprotective and anti-inflammatory effects of Peumus boldusView study →}.

Gap: the human “digestive/choleretic” evidence is for the boldo herb/leaf tea, traditional-use grade, not the isolated alkaloid — and the isolate liver data are rodent-only ^{6,8Reference 61991Hepatoprotective and anti-inflammatory effects of Peumus boldusView study →Reference 82024Boldine protects against CCl₄-induced chronic liver injury via NF-κBView study →}.

3. Anti-inflammatory

Boldine consistently down-modulates NF-κB and inflammatory signalling as a secondary axis to its antioxidant effect, across liver and chemo-toxicity models ^{8,6Reference 82024Boldine protects against CCl₄-induced chronic liver injury via NF-κBView study →Reference 61991Hepatoprotective and anti-inflammatory effects of Peumus boldusView study →}.

Gap: no dedicated inflammatory-disease model with boldine as the primary intervention and a clinical readout — the effect is entangled with its antioxidant action ^{8Reference 82024Boldine protects against CCl₄-induced chronic liver injury via NF-κBView study →}.

4. Anti-diabetic / anti-fibrotic

Boldine avoided a TGF-β rise and kidney damage in a renovascular hypertension model ^{9Reference 92018Boldine improves kidney damage in the Goldblatt 2K1C model, avoiding a TGF-β riseView study →} and inhibited hepatic gluconeogenesis in perfused liver ^{10Reference 102023AnimalInhibition of gluconeogenesis by boldine in the perfused rat liverView study →}, with additional diabetic vascular/endothelial signals.

Gap: scattered across model systems in small studies with no dose-ranging consensus — the anti-fibrotic signal is promising but early ^{9,10Reference 92018Boldine improves kidney damage in the Goldblatt 2K1C model, avoiding a TGF-β riseView study →Reference 102023AnimalInhibition of gluconeogenesis by boldine in the perfused rat liverView study →}.

5. Neuroprotective

Boldine attenuated synaptic failure and mitochondrial deregulation in Alzheimer’s cell models ^{11Reference 112021Boldine attenuates synaptic failure and mitochondrial deregulation in Alzheimer’s disease cell modelsView study →} and showed anticonvulsant activity via its antioxidant action in mice ^{12Reference 122019Acute anticonvulsant effects of boldine via its antioxidant activityView study →}.

Gap: wholly preclinical, mechanistically heterogeneous, and boldine’s blood-brain-barrier penetration is not well established despite the CNS activity ^{11,12Reference 112021Boldine attenuates synaptic failure and mitochondrial deregulation in Alzheimer’s disease cell modelsView study →Reference 122019Acute anticonvulsant effects of boldine via its antioxidant activityView study →}.

6. Dopamine / adrenoceptor activity

Boldine binds α₁-/α₂-adrenoceptors with functional vasorelaxant/antihypertensive actions ^{13Reference 132002Affinity profile at α₁-/α₂-adrenoceptor subtypes and cardiovascular actions of boldineView study →} and acts as a dopamine D1-type antagonist ^{14Reference 141999Biochemical and behavioural effects of boldine and glaucine on dopamine systemsView study →}.

Gap: boldine itself is a relatively low-affinity, non-selective ligand — much of the selectivity literature is on engineered halogenated/amino derivatives, not native boldine — so this is mechanistically interesting, not a therapeutic receptor drug ^{13,14Reference 132002Affinity profile at α₁-/α₂-adrenoceptor subtypes and cardiovascular actions of boldineView study →Reference 141999Biochemical and behavioural effects of boldine and glaucine on dopamine systemsView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Direct radical scavenging (phenolic/aporphine H-donation)	chain-breaking antioxidant; inhibits lipid/LDL peroxidation	antioxidant (marquee)
Nrf2 / ARE	↑ endogenous antioxidant/detox enzymes	cytoprotection
NF-κB	↓ inflammatory signalling	anti-inflammatory, hepatoprotective
FXR / osmotic choleresis	↑ bile flow	choleretic / digestive
TGF-β; hepatic gluconeogenesis	↓ fibrogenesis; ↓ glucose output	anti-fibrotic, glycemic
α₁-adrenoceptor antagonism; dopamine D1 antagonism	vasorelaxation; dopaminergic modulation (low native affinity)	cardiovascular / CNS
Pro-oxidant switch (high concentration)	context-dependent ROS generation	toxicity / dosing ceiling

Pharmacokinetics

Boldine is orally absorbed in rodents but with modest bioavailability and rapid clearance, its systemic exposure limited by first-pass and biliary handling. Disposition studies show substantial biliary, Mrp2-dependent excretion — its pharmacokinetics differ markedly in Mrp2-deficient rats, indicating boldine or its conjugates are an Mrp2 substrate and implying phase-II glucuronide/sulfate conjugation with enterohepatic recycling ^{15Reference 152016AnimalPharmacokinetics of boldine in control and Mrp2-deficient ratsView study →}. Blood-brain-barrier penetration is not firmly quantified despite the CNS activity — a real gap for the neuroprotective claims — and there is essentially no human pharmacokinetics for the isolate; human exposure data are for boldo-leaf preparations.

Clinical trials

There are effectively no trials of isolated boldine. The human evidence base is for the boldo herb (Peumus boldus leaf) in traditional digestive/choleretic use, where the leaf preparation — not the isolated alkaloid — is the product, and efficacy is “traditional use” grade rather than RCT-demonstrated. All boldine-specific pharmacology on this page is preclinical.

Last checked: July 2026.

Toxicity & Safety

Isolated boldine has low-to-moderate acute toxicity and is not the driver of boldo’s worst safety signals — which is the key clarification of the page. Boldo’s hepatotoxicity and abortifacient reputation is largely its essential oil, high in ascaridole (a neurotoxic/hepatotoxic terpene endoperoxide, a separate compound); a documented human hepatotoxicity case involved a boldo-containing laxative, i.e. herb/oil exposure ^{18Reference 182005Caution in the use of boldo in herbal laxatives: a case of hepatotoxicityView study →}. The genuine isolate-level flag is genotoxicity: boldine has reported genotoxic/mutagenic activity in prokaryotic and mammalian test systems ^{16,17Reference 161994Evaluation of the genotoxic potential of boldine in mammalian cell systemsView study →Reference 171991Genotoxicity of the boldine aporphine alkaloid in prokaryotic and eukaryotic organismsView study →}, although it is also widely studied as an antigenotoxic antioxidant — a real dual/pro-oxidant duality, with benefit that is not monotonic (higher concentrations can be pro-oxidant ^{4Reference 42008Antioxidant and pro-oxidant properties of boldine on hippocampal slicesView study →}). No human safety data exist for purified boldine. This combination — reproducible genotoxicity signals, a pro-oxidant ceiling, and the inherited pregnancy contraindication — is why the page is flagged moderate rather than low (the severe boldo liver events belong to the ascaridole/essential-oil page, not here).

Pregnancy & lactation

Avoid — contraindicated. Boldo (whole herb and especially its ascaridole-rich essential oil) is traditionally regarded as abortifacient and contraindicated in pregnancy, and is not recommended during lactation; even though that concern is chiefly an essential-oil issue, boldine’s own unresolved genotoxicity signals and the absence of human safety data warrant a firm avoid in both.

Dosage

There is no established human dose for isolated boldine, and nothing here is a recommendation. As the boldo herb (not the isolate), traditional digestive use is roughly 1–2 g of dried leaf as an infusion up to a few times daily, short-term, with regulatory guidance cautioning against prolonged use and against the essential oil. Preclinical rodent studies commonly use oral boldine in the ~10–100 mg/kg range, but the benefit is non-monotonic (a pro-oxidant ceiling) and these figures do not convert to human guidance — steer to standardised boldo-leaf products, short-term, and avoid boldo essential oil.

References